Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. [electronic resource]
Producer: 20061017Description: 160-9 p. digitalISSN:- 0007-0963
- Abscess -- etiology
- Adult
- Antibodies, Monoclonal -- adverse effects
- Autoantibodies -- blood
- Carcinoma, Basal Cell -- etiology
- Carcinoma, Renal Cell -- etiology
- Cellulitis -- etiology
- Female
- Follow-Up Studies
- Humans
- Hypertension -- etiology
- Immunosuppressive Agents -- adverse effects
- Infliximab
- Kidney Neoplasms -- etiology
- Lentigo -- etiology
- Liver Diseases -- etiology
- Male
- Middle Aged
- Prospective Studies
- Psoriasis -- drug therapy
- Respiratory Tract Infections -- etiology
- Skin Neoplasms -- etiology
- Thrombocytopenia -- etiology
- Time Factors
- Treatment Outcome
- Tuberculosis -- etiology
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.